AstraZeneca CEO Defends Global Impact Of Its COVID-19 Vaccine
Maligned Vaccine Is Biggest Contributor To India, COVAX
Executive Summary
Pascal Soriot said AZ employees should be proud of the COVID-19 vaccine achievements so far, but conceded that manufacturing output would continue to lag.
You may also be interested in...
Coronavirus Update: Moderna Donates More Doses, Booster Shot Shows Efficacy
Novavax said it would start shipping supplies of its vaccine to Europe starting in late 2021, while Vaxart delayed the start of its Phase II study due to issues with Emergent BioSolutions. Meanwhile, Roche India received an EUA for Regeneron's antibody cocktail
UK As New Global Base, Serum Institute Mulls Acquisition Or Greenfield Unit
After setting up a sales base in the UK, Serum Institute could consider an acquisition in Europe or investment in an Oxford facility as it ties up production for its multiple COVID-19 vaccines. Is Wockhardt’s Wrexham facility an option?
Alexion Deal Adds Up For AstraZeneca's Rare Disease Specialist CFO
The proposed $39bn acquisition of Alexion by AstraZeneca has a particular interest for its chief financial officer Marc Dunoyer who recently spoke to Scrip about his extensive experience in the rare disease space.